436 related articles for article (PubMed ID: 24689365)
1. Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.
Lazo L; Izquierdo A; Suzarte E; Gil L; Valdés I; Marcos E; Álvarez M; Romero Y; Guzmán MG; Guillén G; Hermida Cruz L
Microbiol Immunol; 2014 Apr; 58(4):219-26. PubMed ID: 24689365
[TBL] [Abstract][Full Text] [Related]
2. A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates.
Chen HW; Liu SJ; Li YS; Liu HH; Tsai JP; Chiang CY; Chen MY; Hwang CS; Huang CC; Hu HM; Chung HH; Wu SH; Chong P; Leng CH; Pan CH
Arch Virol; 2013 Jul; 158(7):1523-31. PubMed ID: 23456422
[TBL] [Abstract][Full Text] [Related]
3. Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.
Govindarajan D; Meschino S; Guan L; Clements DE; ter Meulen JH; Casimiro DR; Coller BA; Bett AJ
Vaccine; 2015 Aug; 33(33):4105-16. PubMed ID: 26144900
[TBL] [Abstract][Full Text] [Related]
4. A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice.
Izquierdo A; García A; Lazo L; Gil L; Marcos E; Alvarez M; Valdés I; Hermida L; Guillén G; Guzmán MG
Arch Virol; 2014 Oct; 159(10):2597-604. PubMed ID: 24841761
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.
Liu G; Song L; Beasley DW; Putnak R; Parent J; Misczak J; Li H; Reiserova L; Liu X; Tian H; Liu W; Labonte D; Duan L; Kim Y; Travalent L; Wigington D; Weaver B; Tussey L
Clin Vaccine Immunol; 2015 May; 22(5):516-25. PubMed ID: 25761459
[TBL] [Abstract][Full Text] [Related]
6. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.
Suzarte E; Gil L; Valdés I; Marcos E; Lazo L; Izquierdo A; García A; López L; Álvarez M; Pérez Y; Castro J; Romero Y; Guzmán MG; Guillén G; Hermida L
Int Immunol; 2015 Aug; 27(8):367-79. PubMed ID: 25795768
[TBL] [Abstract][Full Text] [Related]
7. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
8. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.
Clements DE; Coller BA; Lieberman MM; Ogata S; Wang G; Harada KE; Putnak JR; Ivy JM; McDonell M; Bignami GS; Peters ID; Leung J; Weeks-Levy C; Nakano ET; Humphreys T
Vaccine; 2010 Mar; 28(15):2705-15. PubMed ID: 20097152
[TBL] [Abstract][Full Text] [Related]
9. A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice.
Lazo L; Gil L; López C; Valdés I; Blanco A; Pavón A; Romero Y; Guzmán MG; Guillén G; Hermida L
Acta Trop; 2012 Nov; 124(2):107-12. PubMed ID: 22750482
[TBL] [Abstract][Full Text] [Related]
10. Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use.
Valdés I; Hermida L; Gil L; Lazo L; Castro J; Martín J; Bernardo L; López C; Niebla O; Menéndez T; Romero Y; Sánchez J; Guzmán MG; Guillén G
Int J Infect Dis; 2010 May; 14(5):e377-83. PubMed ID: 19773190
[TBL] [Abstract][Full Text] [Related]
11. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
12. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis.
Valdés I; Hermida L; Martín J; Menéndez T; Gil L; Lazo L; Castro J; Niebla O; López C; Bernardo L; Sánchez J; Romero Y; Martínez R; Guzmán MG; Guillén G
Vaccine; 2009 Feb; 27(7):995-1001. PubMed ID: 19100804
[TBL] [Abstract][Full Text] [Related]
13. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.
Brandler S; Ruffie C; Najburg V; Frenkiel MP; Bedouelle H; Desprès P; Tangy F
Vaccine; 2010 Sep; 28(41):6730-9. PubMed ID: 20688034
[TBL] [Abstract][Full Text] [Related]
14. Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys.
Gil L; Izquierdo A; Lazo L; Valdés I; Ambala P; Ochola L; Marcos E; Suzarte E; Kariuki T; Guzmán G; Guillén G; Hermida L
Virology; 2014 May; 456-457():70-6. PubMed ID: 24889226
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical development of a dengue recombinant subunit vaccine.
Manoff SB; George SL; Bett AJ; Yelmene ML; Dhanasekaran G; Eggemeyer L; Sausser ML; Dubey SA; Casimiro DR; Clements DE; Martyak T; Pai V; Parks DE; Coller BA
Vaccine; 2015 Dec; 33(50):7126-34. PubMed ID: 26458804
[TBL] [Abstract][Full Text] [Related]
16. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S; Pilankatta R; Khanna N; Swaminathan S
Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
[TBL] [Abstract][Full Text] [Related]
17. A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses.
Valdés I; Marcos E; Suzarte E; Pérez Y; Brown E; Lazo L; Cobas K; Yaugel M; Rodríguez Y; Gil L; Guillén G; Hermida L
Arch Virol; 2017 Aug; 162(8):2247-2256. PubMed ID: 28393307
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
Metz SW; Thomas A; Brackbill A; Xianwen Y; Stone M; Horvath K; Miley MJ; Luft C; DeSimone JM; Tian S; de Silva AM
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006793. PubMed ID: 30248097
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.
Bernardo L; Izquierdo A; Alvarez M; Rosario D; Prado I; López C; Martínez R; Castro J; Santana E; Hermida L; Guillen G; Guzmán MG
Antiviral Res; 2008 Nov; 80(2):194-9. PubMed ID: 18602424
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine.
Porter KR; Ewing D; Chen L; Wu SJ; Hayes CG; Ferrari M; Teneza-Mora N; Raviprakash K
Vaccine; 2012 Jan; 30(2):336-41. PubMed ID: 22085548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
